To complete this preliminary study 53 patients were chosen. All patients were screened, diagnosed for
Hepatitis A or
Hepatitis B and separated into treatment and control groups. All of the patients selected were in the early onset stage of their
infection, and diagnosed for
Hepatitis A or B by appropriate laboratory tests with special attention to
Anti-HAV,
IGM and
HepB surface Antigen to carefully differentiate those with A from those with B. The treated patients received
Reticulose for a 15 day period and the control patients received placebo
injections of physiological saline.
Reticulose patients with
Hepatitis showed positive. 18 patients with
Hepatitis B and 9 patients with
Hepatitis A were treated with
Reticulose, compared to 17 control patients with
Hepatitis B and 9 control patients with
Hepatitis A treated with placebo. Based upon laboratory findings of several parameters; Prothrombin times, Serum
bilirubin, white blood cell (WBC count) and clinical observations;
Reticulose treated patients appeared to show significant improvement. The
bilirubin levels of 83% of patients with
Hepatitis B, treated with
Reticulose for 15 days were in normal range in 30 days. None of the control patients were within normal range after 30 days with placebo treatment. Of
Hepatitis A patients treated with
Reticulose, 100% showed normal
bilirubin after 30 days. Of control patients with
Hepatitis A, only 22% were in normal range after 30 days. The findings in this preliminary trial lead to the conclusion that
Reticulose appears to significantly reduce the recovery time and return to normal for patients with an acute episode of
Hepatitis A or B. Further study is indicated.